Last mentioned: May 5, 2026
Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 diabetes trial, a result that matches or slightly trails the performance of its own blockbuster Mounjaro. While the glucose-lowering data is robust, the market's primary interest remains focused on the drug's potential for industry-leading weight loss and metabolic benefits.
This page surfaces every story mentioning Mounjaro across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Mounjaro was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |